Large Remdesivir Study Finds No COVID-19 Survival Benefit. Why do the TGA allow it to be used?

A lack of consensus regarding the antiviral drug remdesivir to treat people with COVID-19 continues, leaving doctors without clear direction on one of the few treatments for the illness the TGA has granted emergency use authorisation.

The latest research comes from Michael Ohl, MD, and colleagues who studied a large group of Veterans Administration patients hospitalized with COVID-19. Compared with a matched group of veterans who did not receive the antiviral, remdesivir did not significantly improve survival rates.